Trial Profile
A double-blind, randomised, placebo controlled, phase I/IIa dose escalation study to investigate the safety and tolerability of Oralgen Birch Pollen immunotherapy in patients with allergic rhinoconjunctivitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jul 2011
Price :
$35
*
At a glance
- Drugs Birch pollen allergy immunotherapy (Primary)
- Indications Allergic conjunctivitis; Allergic rhinitis; Rhinoconjunctivitis
- Focus Adverse reactions
- 06 Jul 2011 New trial record